Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blood advances

Showing results (1-10 of 6,133) with videos related to

Pageof 614
Sort By:
Blood Advances|November 22, 2021
The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United StatesNaomi C Sacks, Bridget E Healey, Sajjad Raza, et al.
Blood Advances|November 22, 2021
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trialVincent T Ho, Haesook T Kim, Jennifer Brock, et al.
Blood Advances|November 22, 2021
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myelomaMeera Mohan, Samantha Kendrick, Aniko Szabo, et al.
Blood Advances|November 23, 2021
Induced cell-autonomous neutropenia systemically perturbs hematopoiesis in Cebpa enhancer-null miceRoberto Avellino, Roger Mulet-Lazaro, Marije Havermans, et al.
Blood Advances|November 8, 2021
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataLaurie H Sehn, Mark Hertzberg, Stephen Opat, et al.
Blood Advances|November 9, 2021
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantationMuna Qayed, Benjamin Watkins, Scott Gillespie, et al.
Blood Advances|November 15, 2021
Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemiaYuki Morimoto, Kazuhisa Chonabayashi, Hiroshi Kawabata, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Blood Advances|November 12, 2021
Antithrombin protects against Plasmodium falciparum histidine-rich protein II-mediated inflammation and coagulationIndranil Biswas, Sumith R Panicker, Hemant Giri, et al.
Pageof 614

Showing results (1-10 of 6,133) with videos related to

Sort By:
Pageof 614
Blood Advances|November 22, 2021
The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United StatesNaomi C Sacks, Bridget E Healey, Sajjad Raza, et al.
Blood Advances|November 22, 2021
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trialVincent T Ho, Haesook T Kim, Jennifer Brock, et al.
Blood Advances|November 22, 2021
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myelomaMeera Mohan, Samantha Kendrick, Aniko Szabo, et al.
Blood Advances|November 23, 2021
Induced cell-autonomous neutropenia systemically perturbs hematopoiesis in Cebpa enhancer-null miceRoberto Avellino, Roger Mulet-Lazaro, Marije Havermans, et al.
Blood Advances|November 8, 2021
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataLaurie H Sehn, Mark Hertzberg, Stephen Opat, et al.
Blood Advances|November 9, 2021
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantationMuna Qayed, Benjamin Watkins, Scott Gillespie, et al.
Blood Advances|November 15, 2021
Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemiaYuki Morimoto, Kazuhisa Chonabayashi, Hiroshi Kawabata, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Blood Advances|November 12, 2021
Antithrombin protects against Plasmodium falciparum histidine-rich protein II-mediated inflammation and coagulationIndranil Biswas, Sumith R Panicker, Hemant Giri, et al.
Pageof 614